Fig. 2. Induction of anti–NY-ESO-1 IgG titers in patients vaccinated with CDX-1401.
Pre- and posttreatment sera were tested for anti–NYESO-1 IgG responses by enzyme-linked immunosorbent assay (ELISA) using full-length recombinant NY-ESO-1. The titer was established by determining the endpoint dilution with the peak response shown by color map as indicated in the legend. Patients with archival tumor that demonstrated NY-ESO-1 expression by IHC or PCR are indicated with green shading. Patients who experienced stable disease are indicated by asterisk.